Hereditary Gastric Cancer Is Linked With Hereditary Breast and Ovarian Cancer
- PMID: 38993249
- PMCID: PMC11236378
- DOI: 10.14740/wjon1871
Hereditary Gastric Cancer Is Linked With Hereditary Breast and Ovarian Cancer
Abstract
Background: Helicobacter pylori (H. pylori), a bacterium which chronically infects the stomach of approximately half the world's population, is a risk factor for the development of gastric cancer (GC). However, the underlying mechanism whereby H. pylori infection induces GC development remains unclear. Intermittent injection of the H. pylori cytotoxin-associated gene A antigen (CagA) protein into its host cell inhibits nuclear translocation of BRCA1/BRCA2, DNA repair proteins involved in the development of breast cancer/ovarian cancer. Interestingly, hereditary breast and ovarian cancer (HBOC) syndrome is associated with GC development. Here, we aimed to clarify the molecular link between H. pylori infection, BRCA1/2 pathogenic variants (PVs), GC and higher GC incidence in HBOC families.
Methods: We retrospectively reviewed data from Japanese patients undergoing precision treatment using cancer genomic medicine.
Results: We found a higher GC incidence in HBOC families having germline pathogenic variants (GPVs) of BRCA1/2 (2.95% vs. 0.78% in non-HBOC families). Next, we found that 96.1% of H. pylori-infected patients received cancer genomic medicine for advanced GC, and > 16% advanced GC patients had gBRCA2 PVs. Furthermore, expressing wild-type BRCA1/2 in Gan mice (a mouse model of human GC) inhibited GC development. Thus, gBRAC1/2 PVs and H. pylori infection synergistically increase the risk of GC development.
Conclusion: Our study highlights the need to investigate the potential of therapeutic agents against BRCA1/2 PVs to avoid the development of GC in HBOC families. In addition, our results suggest that poly (ADP-ribose) polymerase (PARP) inhibitors could potentially inhibit GC development and progression with gBRCA1/2 PVs.
Keywords: BRCA1; BRCA2; Gastric cancer; HBOC; Helicobacter pylori.
Copyright 2024, Hayashi et al.
Conflict of interest statement
The authors state no competing interest.
Figures



Similar articles
-
Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients with Gastric Cancer Associated with Hereditary Breast and Ovarian Cancer.Curr Oncol. 2024 Oct 29;31(11):6723-6734. doi: 10.3390/curroncol31110496. Curr Oncol. 2024. PMID: 39590127 Free PMC article.
-
Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing.Pathol Res Pract. 2024 Feb;254:155075. doi: 10.1016/j.prp.2023.155075. Epub 2024 Jan 2. Pathol Res Pract. 2024. PMID: 38219492
-
Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population.BMC Med Genomics. 2020 Feb 10;13(1):21. doi: 10.1186/s12920-019-0652-y. BMC Med Genomics. 2020. PMID: 32039725 Free PMC article.
-
[Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].Gan To Kagaku Ryoho. 2014 Nov;41(11):1333-9. Gan To Kagaku Ryoho. 2014. PMID: 25434434 Review. Japanese.
-
Gastric Cancer Risk and Pathogenesis in BRCA1 and BRCA2 Carriers.Cancers (Basel). 2022 Dec 1;14(23):5953. doi: 10.3390/cancers14235953. Cancers (Basel). 2022. PMID: 36497436 Free PMC article. Review.
References
-
- Fiocca R, Villani L, Tenti P, Solcia E, Cornaggia M, Frigerio B, Capella C. Characterization of four main cell types in gastric cancer: foveolar, mucopeptic, intestinal columnar and goblet cells. An histopathologic, histochemical and ultrastructural study of "early" and "advanced" tumours. Pathol Res Pract. 1987;182(3):308–325. doi: 10.1016/S0344-0338(87)80066-3. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous